Qiagen N.V. (NYSE:QGEN) Receives Consensus Recommendation of “Hold” from Analysts

Qiagen N.V. (NYSE:QGEN) has received an average rating of “Hold” from the twelve analysts that are currently covering the stock, Marketbeat.com reports. Nine analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $49.4008.

Several research firms have recently issued reports on QGEN. UBS Group raised their price objective on Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Barclays set a $53.00 price objective on Qiagen and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a report on Saturday. Bank of America increased their target price on Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a research report on Thursday, June 26th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Qiagen in a research report on Wednesday.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. GAMMA Investing LLC raised its position in shares of Qiagen by 375.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock worth $55,000 after buying an additional 980 shares during the period. Osaic Holdings Inc. raised its position in shares of Qiagen by 101.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock worth $185,000 after buying an additional 1,951 shares during the period. Orion Porfolio Solutions LLC raised its position in shares of Qiagen by 120.6% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 29,361 shares of the company’s stock worth $1,411,000 after buying an additional 16,054 shares during the period. Squarepoint Ops LLC raised its position in shares of Qiagen by 11.4% in the 2nd quarter. Squarepoint Ops LLC now owns 13,548 shares of the company’s stock worth $651,000 after buying an additional 1,386 shares during the period. Finally, Neuberger Berman Group LLC raised its position in shares of Qiagen by 57.5% in the 2nd quarter. Neuberger Berman Group LLC now owns 30,478 shares of the company’s stock worth $1,463,000 after buying an additional 11,126 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $46.93 on Friday. The business’s fifty day moving average price is $47.11 and its two-hundred day moving average price is $45.50. The stock has a market cap of $10.43 billion, a PE ratio of 27.73, a price-to-earnings-growth ratio of 2.46 and a beta of 0.66. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. Qiagen has a one year low of $37.63 and a one year high of $51.88.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The business had revenue of $533.54 million for the quarter, compared to analysts’ expectations of $523.97 million. During the same quarter last year, the firm earned $0.55 earnings per share. The business’s revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, analysts forecast that Qiagen will post 2.26 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.